iScience (Jun 2018)

Marked Global DNA Hypomethylation Is Associated with Constitutive PD-L1 Expression in Melanoma

  • Aniruddha Chatterjee,
  • Euan J. Rodger,
  • Antonio Ahn,
  • Peter A. Stockwell,
  • Matthew Parry,
  • Jyoti Motwani,
  • Stuart J. Gallagher,
  • Elena Shklovskaya,
  • Jessamy Tiffen,
  • Michael R. Eccles,
  • Peter Hersey

Journal volume & issue
Vol. 4
pp. 312 – 325

Abstract

Read online

Summary: Constitutive expression of the immune checkpoint, PD-L1, inhibits anti-tumor immune responses in cancer, although the factors involved in PD-L1 regulation are poorly understood. Here we show that loss of global DNA methylation, particularly in intergenic regions and repeat elements, is associated with constitutive (PD-L1CON), versus inducible (PD-L1IND), PD-L1 expression in melanoma cell lines. We further show this is accompanied by transcriptomic up-regulation. De novo epigenetic regulators (e.g., DNMT3A) are strongly correlated with PD-L1 expression and methylome status. Accordingly, decitabine-mediated inhibition of global methylation in melanoma cells leads to increased PD-L1 expression. Moreover, viral mimicry and immune response genes are highly expressed in lymphocyte-negative plus PD-L1-positive melanomas, versus PD-L1-negative melanomas in The Cancer Genome Atlas (TCGA). In summary, using integrated genomic analysis we identified that global DNA methylation influences PD-L1 expression in melanoma, and hence melanoma's ability to evade anti-tumor immune responses. These results have implications for combining epigenetic therapy with immunotherapy. : Genetics; Genomics; Cancer; Transcriptomics Subject Areas: Genetics, Genomics, Cancer, Transcriptomics